Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease

Status: Recruiting
Location: See location...
Intervention Type: Radiation, Procedure, Genetic, Behavioral
Study Type: Observational
SUMMARY

The study is designed to characterize the clinical, neuropsychological, polysomnographic, and neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and Parkinsons' Disease.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Subjects must meet the standard clinical criteria of the syndromes of interest

• All subjects must have enough cognitive abilities to complete study procedures, which will be operationally defined as having a Mini Mental State Examination (MMSE) score greater or equal to 10.

• Subjects must be on stable cognitive and psychoactive medication regimen for the preceding four weeks of enrollment.

• Subjects must have a responsible study partner that either lives with them or is in regular contact with them at least 4 out of 7 days per week.

• Subjects must have visual and auditory acuity adequate for testing.

Locations
United States
Ohio
The Ohio State University
RECRUITING
Columbus
Contact Information
Primary
Jennifer Icenhour
jennifer.icenhour@osumc.edu
614-293-6882
Time Frame
Start Date: 2018-08-30
Estimated Completion Date: 2026-12
Participants
Target number of participants: 76
Treatments
Alzheimer's disease
Individuals with a clinical diagnosis of Alzheimer's disease will undergo the interventions including DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, and Clinical Assessment.
Lewy Body dementia
Individuals with a clinical diagnosis of Lewy Body Dementia will undergo the interventions including DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, and Clinical Assessment.
Parkinson's disease
Individuals with a clinical diagnosis of Parkinson's disease will undergo the interventions including DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, and Clinical Assessment.
Sponsors
Collaborators: Mangurian Foundation, Avid Radiopharmaceuticals
Leads: Douglas Scharre

This content was sourced from clinicaltrials.gov